CN118401249A - 用于治疗疼痛的肽和方法 - Google Patents

用于治疗疼痛的肽和方法 Download PDF

Info

Publication number
CN118401249A
CN118401249A CN202280083300.3A CN202280083300A CN118401249A CN 118401249 A CN118401249 A CN 118401249A CN 202280083300 A CN202280083300 A CN 202280083300A CN 118401249 A CN118401249 A CN 118401249A
Authority
CN
China
Prior art keywords
peptide
pain
seq
vector
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280083300.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·盖拉德
F·卡斯特茨
A·莫克里赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tafajis Biotechnology Co
Original Assignee
Tafajis Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tafajis Biotechnology Co filed Critical Tafajis Biotechnology Co
Publication of CN118401249A publication Critical patent/CN118401249A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280083300.3A 2021-12-17 2022-12-19 用于治疗疼痛的肽和方法 Pending CN118401249A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306835.6 2021-12-17
EP21306835 2021-12-17
PCT/EP2022/086559 WO2023111348A1 (en) 2021-12-17 2022-12-19 Peptides and methods for use in treating pain

Publications (1)

Publication Number Publication Date
CN118401249A true CN118401249A (zh) 2024-07-26

Family

ID=79317102

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280083300.3A Pending CN118401249A (zh) 2021-12-17 2022-12-19 用于治疗疼痛的肽和方法

Country Status (12)

Country Link
US (1) US20250051395A1 (cg-RX-API-DMAC7.html)
EP (1) EP4447991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547029A (cg-RX-API-DMAC7.html)
KR (1) KR20240126864A (cg-RX-API-DMAC7.html)
CN (1) CN118401249A (cg-RX-API-DMAC7.html)
AR (1) AR129864A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022413983A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239578A1 (cg-RX-API-DMAC7.html)
IL (1) IL313183A (cg-RX-API-DMAC7.html)
MX (1) MX2024007301A (cg-RX-API-DMAC7.html)
TW (1) TW202344689A (cg-RX-API-DMAC7.html)
WO (1) WO2023111348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
TW202344689A (zh) 2023-11-16
JP2024547029A (ja) 2024-12-26
AU2022413983A1 (en) 2024-06-13
KR20240126864A (ko) 2024-08-21
CA3239578A1 (en) 2023-06-22
MX2024007301A (es) 2024-06-26
AR129864A1 (es) 2024-10-09
US20250051395A1 (en) 2025-02-13
EP4447991A1 (en) 2024-10-23
WO2023111348A1 (en) 2023-06-22
IL313183A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
Zeng et al. RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis
JP7366388B2 (ja) 抗Ryk抗体およびその使用方法
You et al. Ablation of NLRP3 inflammasome attenuates muscle atrophy via inhibiting pyroptosis, proteolysis and apoptosis following denervation
JP7097070B2 (ja) クロライドチャネルの標的発現及びその使用方法
US20250051395A1 (en) Peptides and methods for use in treating pain
US20250213654A1 (en) Peptides and methods for use in treating pain
AU2019304569B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
CN111467479A (zh) 眼镜蛇科蛇突触后神经毒素单体分子在治疗老年痴呆上的应用
JP5746616B2 (ja) ペプチドトキシンAPETx2の鎮痛作用
AU2014233219B2 (en) Methods for treatment of nephrotic syndrome and related conditions
EP1080111B1 (en) The induction of antiobiotic peptides by lait (scd14) protein
HK1243732A1 (zh) 编码hnp-1或hnp-2或hnp-3的dna质粒、细菌生产者、镇痛剂(变体)
OA22140A (en) Peptides and methods for use in treating pain.
OA22072A (en) Peptides and methods for use in treating pain.
KR20130122927A (ko) Dkk2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
CN101525602A (zh) 制备抗pink1多克隆抗血清的多肽及其应用
WO2005053729A1 (en) Stem cell factor for inducing neural stem cell migration to areas of neurological injury
WO2012097256A1 (en) Therapeutic compositions and methods for disorders associated with neuronal degeneration
KR20130126549A (ko) 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
EP0686194A1 (fr) Facteurs de croissance de la famille de l'harp, procede d'obtention et applications
Johnson et al. AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease
WO2023240086A9 (en) Humanized non-opioid composition and therapies for pain management
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
CN1919868B (zh) 慢性神经痛相关蛋白及其基因
Xu The Effect of Neonatal Administration of Recombinant Myostatin Propeptide on Skeletal Muscle Growth in Mice.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination